[
  {
    "ts": "2025-11-04T14:00:00+00:00",
    "headline": "Dispatch Bio Announces Clinical Supply and Collaboration Agreement with Bristol Myers Squibb in Solid Tumors",
    "summary": "PHILADELPHIA & SAN FRANCISCO, November 04, 2025--Dispatch Bio, a biotech company engineering a universal treatment across solid tumors leveraging its first-in-class Flare platform, today announced a clinical supply and collaboration agreement with Bristol Myers Squibb (\"BMS\") to support the development of Dispatch’s DISP-10 program. Under the agreement, BMS will provide idecabtagene vicleucel (ide-cel), a BCMA-directed CAR T therapy, for use in Dispatch’s first U.S. Phase 1 trial, expected to in",
    "url": "https://finance.yahoo.com/news/dispatch-bio-announces-clinical-supply-140000920.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "08772e57-c4de-30f7-8f8c-3b41b827cfd1",
      "content": {
        "id": "08772e57-c4de-30f7-8f8c-3b41b827cfd1",
        "contentType": "STORY",
        "title": "Dispatch Bio Announces Clinical Supply and Collaboration Agreement with Bristol Myers Squibb in Solid Tumors",
        "description": "",
        "summary": "PHILADELPHIA & SAN FRANCISCO, November 04, 2025--Dispatch Bio, a biotech company engineering a universal treatment across solid tumors leveraging its first-in-class Flare platform, today announced a clinical supply and collaboration agreement with Bristol Myers Squibb (\"BMS\") to support the development of Dispatch’s DISP-10 program. Under the agreement, BMS will provide idecabtagene vicleucel (ide-cel), a BCMA-directed CAR T therapy, for use in Dispatch’s first U.S. Phase 1 trial, expected to in",
        "pubDate": "2025-11-04T14:00:00Z",
        "displayTime": "2025-11-04T14:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/d9e4df3e6c0fa655ee4d319afa56a5e7",
          "originalWidth": 1024,
          "originalHeight": 512,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/P0lH_JwflzTCiOiG4iCAeA--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/d9e4df3e6c0fa655ee4d319afa56a5e7.cf.webp",
              "width": 1024,
              "height": 512,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/V2.PHX23NGOal9LRmT8LvQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/d9e4df3e6c0fa655ee4d319afa56a5e7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/dispatch-bio-announces-clinical-supply-140000920.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/dispatch-bio-announces-clinical-supply-140000920.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]